Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Oncologist & Diagnostics Conference Brussels, Belgium.

Day 1 :

Keynote Forum

Julia Gerasimenko

Cardiff University

Keynote: Special session

Time : 13:00-13:30

OMICS International Cancer Diagnostics 2017 International Conference Keynote Speaker Julia Gerasimenko photo
Biography:

Julia V Gerasimenko has completed her PhD in 1996 from Bogomoletz Institute of Physiology, Kiev, Ukraine. She is a Senior Lecturer in Cardiff School of Biosciences, Cardiff University, UK. She has published 33 papers in reputed journals and has been serving as an Editorial Board Member of repute. She is a Member of Faculty of 1000 (Gastro-intestinal Physiology), The Physiological Society (UK), British Society for Cell Biology, European Calcium Society. She was an invited speaker for many scientific conferences in the UK and abroad.

 

Abstract:

Confidential

Break: 12:10-13:00
OMICS International Cancer Diagnostics 2017 International Conference Keynote Speaker Jan Jacques Michiels  photo
Biography:

Prof. Dr. J. J. Michiels Multidisciplinairy Internist Blood Coagulation & Vascular Medicine Center, Erasmus Tower, Veenmos 13, 3069 AT Rotterdam, NL, Professor of Nature Medicine & Health Clinical and Molecular Genetics Blood & Coagulation Research, University Hospitals Antwerp, Brussels and Martin-Bratislava International Consultant Bloodcoagulation & Vascular Medicine Consultant Academic, Pharmaceutical and Industrial Medicine Editor Journal of Hematology & Thromboembolic Diseases, Editor World Journal of Hematology, Editor in Chief World Journal of Clinical Cases.

Abstract:

The broad spectrum of JAK2V617F mutated trilinear phenotypes varies from essential thrombocythemia (ET), prodromal polycythemia vera (PV), masked PV, erythrocythemic PV, classical PV, and PV complicated by splenomegaly and myelofibrosis (MF). ET heterozygous for the JAK2V617F mutation is associated with normal life expectanc. JAK2 mutation load increases from less than 50% in early stage PV to 100% in overt and advanced PV and MF. Pretreatment bone marrow morphology and cellularity distinguish JAK2V617F mutated trilinear MPN from calreticulin (CALR) and MPL mutated MPN. The morphology of clustered large pleomorphic megakaryocytes with hyperlobulated nuclei are similar in JAK2V67F ET and PV patients. CALR mutated thrombocythemia shows characteristic bone marrow features of primary dual megakaryocytic granulocytic myeloproliferation (PMGM) without features of PV. MPL515 mutated thrombocythemia is featured by monolinear proliferation of large to giant megakaryocytes with hyperlobulated staghorn like nuclei. JAK2, CALR and MPL allele burden slowly increases together with the degree of splenomegaly, myelofibrosis and constitutional symptoms during life long follow-up. The presence of epigenetic mutations at increasing age predict unfavorable outcome in JAK2, CALR and MPL mutated MPN. Low dose aspirin in ET and phlebotomy on top of aspirin in PV is mandatory to prevent platelet-mediated microvascular circulation disturbances. Pegaylated interferon is the first line myeloreductive treatment option in prodromal and early stage JAK2 mutated PV and in CALR and MPL mutated thrombocythemia to postpone the use of hydrozyurea as long as possible.

Break: 10:45-11:00
OMICS International Cancer Diagnostics 2017 International Conference Keynote Speaker Dr. Wassil Nowicky photo
Biography:

Dr Nowicky has received degree of a Dr. Sci. Tech at the University of Vienna. He is the director of Nowicky Farma and a the inventor of the anticancer preparation NSC631570. Dr. Wassil Nowicky is a real member of the New York Academy of Sciences, member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, doctor “honoris causa” of the Open international university on complex medicine in Colombo, honorary member of the Austrian Society of a name of Albert Schweizer. He has published more than 49 papers in reputed journals. 

Abstract:

One of the most significant problems of cancer therapy is the damaging activity of anticancer drugs against normal body cells. All attempts to develop a therapeutic agent with a selective cytotoxic effect on tumor cells had no much success because of the high degree of biological identity between healthy and malignant cells. The celandine is being used in the medicine over more than 3500 years. The first data concerning the therapeutic effect of the juice of celandine in the patient with malignant melanoma were published in Germany in 1536. From that time drugs based on biologically active substances of celandine are widely used to treat cancer and non-cancer disease. It is well known that tumor cell is more negatively charged as compared to normal cell. We have used this feature of the tumor cell to give NSC631570 a property to selectively interact with it, without endangering healthy cells and tissues. The drug is strongly positively charged. Due to this it has an ability to be selectively accumulated in tumor tissue and to induce tumor cell apoptosis only in tumor cells without harmful effect on normal cells. Potent selective antitumor effect of NSC631570 repeatedly proven by the results of clinical trials. There is an assumption that the same high selective cytotoxicity of drug on tumor cells of different origin is the result of its interaction with an ubiquitous tumor-specific (or overexpressed in tumor cells) compound involved in the induction of cell death. However, this compound remains to be found. 

Break: 10:45-11:00

Keynote Forum

Nick Kostovic,

Kostovic Acupuncture by bio Electron’s Laser, Corp, USA

Keynote: Workshop

Time : 15:30-16:00

OMICS International Cancer Diagnostics 2017 International Conference Keynote Speaker Nick Kostovic, photo
Biography:

Nick Kostovic, for the first time in recorded history have eliminated magnetic from regular electromagnetic electricity. I also created the next six steps described below. I did this by developing a proprietary way of reversed current RC to create what is bio electricity. The device I created is called the Kostovic BioTechnological Energizer, K-BTE Medical Laser Device. This device has been confirmed and recognized as a medical device in September of 2014 by the FDA according to US Law Act Code 201. My entire life's work is a novel process of marrying electrotherapy, physics and Chinese Acupuncture Medicine to create a paradigm breaking instrument of health. Nobody in the world has ever achieved my results.

Abstract:

Break: 15:10-15:30